newsfilter
← Latest News
GlobeNewswire·

Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to